In the present study, we sought to test the hypothesis that drugs that selectively or preferentially modulate α6-containing GABAA receptors in vitro will exert anti-tremor effects in the harmaline model in vivo at well-tolerated doses, and in α6-dependent fashion, as assessed by comparing results from WT mice with those from α6 KO littermates. The gene discussed is TWF1; the disease is Tremor.